RNA biomarkers to facilitate the identification of aggressive prostate cancer.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Molecular Aspects of Medicine

• Publication date

  2015-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.mam.2015.05.003PMID 26022941PMCID PMC4637232
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer screening in the United States, 2015: A review of current American Cancer Society guidelines and current issues in cancer screening

  2015cited by this paper
• The landscape of long noncoding RNAs in the human transcriptome

  2015cited by this paper
• A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.

  2015cited by this paper
• Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.

  2015cited by this paper
• Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer.

  2015cited by this paper
• Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer

  2015cited by this paper
• A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.

  2015cited by this paper
• Radical prostatectomy or watchful waiting in early prostate cancer.

  2014cited by this paper
• AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

  2014influential reference
• A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

  2014influential reference
• The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer

  2014influential reference
• Whole Transcriptome Sequencing Reveals Extensive Unspliced mRNA in Metastatic Castration-Resistant Prostate Cancer

  2014cited by this paper
• Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy

  2014cited by this paper
• Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

  2014cited by this paper
• Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy.

  2014cited by this paper
• RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.

  2014influential reference
• Evidence for Molecular Differences in Prostate Cancer between African American and Caucasian Men

  2014cited by this paper
• The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer

  2014cited by this paper
• Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence.

  2014influential reference
• A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer

  2014cited by this paper
• Can urinary PCA3 supplement PSA in the early detection of prostate cancer?

  2014cited by this paper
• An expression signature at diagnosis to estimate prostate cancer patients' overall survival

  2014cited by this paper
• Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy.

  2014cited by this paper
• TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.

  2014cited by this paper
• Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer

  2014cited by this paper
• Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2–10 ng/ml

  2013cited by this paper
• Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?

  2013cited by this paper
• Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.

  2013cited by this paper
• Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy

  2013influential reference
• Circulating microRNA Profiling Identifies a Subset of Metastatic Prostate Cancer Patients with Evidence of Cancer-Associated Hypoxia

  2013cited by this paper
• Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

  2013cited by this paper
• Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies

  2013influential reference
• Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study

  2013cited by this paper
• A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy

  2013cited by this paper
• Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.

  2013cited by this paper
• A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers.

  2013cited by this paper
• Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy

  2013cited by this paper
• PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.

  2013cited by this paper
• Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.

  2013cited by this paper
• Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low‐risk, localized prostate cancer

  2013influential reference
• PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.

  2013cited by this paper
• Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer.

  2013cited by this paper
• Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.

  2013cited by this paper
• The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex

  2013cited by this paper
• Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer.

  2013cited by this paper
• A Molecular Signature Predictive of Indolent Prostate Cancer

  2013influential reference
• The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis

  2012cited by this paper
• Prostate-cancer mortality at 11 years of follow-up.

  2012cited by this paper
• Chronic prostatitis does not influence urinary PCA3 score

  2012cited by this paper
• ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer

  2012cited by this paper
• MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening

  2012cited by this paper
• Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

  2012cited by this paper
• Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

  2012cited by this paper
• GENCODE: The reference human genome annotation for The ENCODE Project

  2012cited by this paper
• Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement

  2012cited by this paper
• New data on prostate-cancer mortality after PSA screening.

  2012cited by this paper
• Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

  2012cited by this paper
• Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease

  2012influential reference
• Letters to the Editor/Errata Re: Complications after Prostate Biopsy: Data from SEER-Medicare

  2012cited by this paper
• Radical prostatectomy versus observation for localized prostate cancer.

  2012cited by this paper
• Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.

  2012cited by this paper
• Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases.

  2012cited by this paper
• Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.

  2012cited by this paper
• The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression

  2012cited by this paper
• A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study.

  2012influential reference
• Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer.

  2012cited by this paper
• Complications after prostate biopsy: data from SEER-Medicare.

  2011cited by this paper
• ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy

  2011cited by this paper
• TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african‐american and japanese patients

  2011cited by this paper
• mRNA expression signature of Gleason grade predicts lethal prostate cancer.

  2011cited by this paper
• Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force

  2011cited by this paper
• Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases

  2011cited by this paper
• A Tri-Marker Proliferation Index Predicts Biochemical Recurrence after Surgery for Prostate Cancer

  2011cited by this paper
• A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities

  2011cited by this paper
• Circulating miRNAs are correlated with tumor progression in prostate cancer

  2011cited by this paper
• AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression

  2011cited by this paper
• A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

  2011cited by this paper
• Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

  2011influential reference
• Transcriptome Sequencing Identifies PCAT-1, a Novel lincRNA Implicated in Prostate Cancer Progression

  2011cited by this paper
• Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA

  2011influential reference
• Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival

  2011cited by this paper
• ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples

  2010cited by this paper
• Cancer Screening in the United States, 2010: A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening

  2010cited by this paper
• Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

  2010cited by this paper
• Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

  2010cited by this paper
• PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.

  2010cited by this paper
• MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.

  2009cited by this paper
• Cancer-associated regulation of alternative splicing

  2009cited by this paper
• Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States

  2009cited by this paper
• Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.

  2009influential reference
• A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.

  2009influential reference
• Circulating microRNAs as stable blood-based markers for cancer detection

  2008cited by this paper
• Quality of life and satisfaction with outcome among prostate-cancer survivors.

  2008cited by this paper
• Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

  2008cited by this paper
• PCA3: a molecular urine assay for predicting prostate biopsy outcome.

  2008cited by this paper
• Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.

  2008cited by this paper
• Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.

  2008cited by this paper
• Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications

  2008cited by this paper
• Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer

  2007cited by this paper
• The Time-Resolved Fluorescence-Based PCA3 Test on Urinary Sediments after Digital Rectal Examination; a Dutch Multicenter Validation of the Diagnostic Performance

  2007cited by this paper

• Pan-cancer analysis of co-inhibitory molecules revealing their potential prognostic and clinical values in immunotherapy

  2025cites this paper
• Circulating Free RNA as a Therapeutic Evaluation in Diffuse Large B-cell Lymphoma: A Case Series from the Indonesian Cancer Center.

  2024cites this paper
• Methodology for Isolation of miRNA From the Serum of Women Investigated for Pre-eclampsia

  2023cites this paper
• Liquid Biopsies, Novel Approaches and Future Directions

  2023cites this paper
• Epigenetics in precision medicine of cardiovascular disease

  2022cites this paper
• Precision Oncology, Signaling and Anticancer Agents in Cancer Therapeutics.

  2021cites this paper
• mRBioM: An Algorithm for the Identification of Potential mRNA Biomarkers From Complete Transcriptomic Profiles of Gastric Adenocarcinoma

  2021cites this paper
• Downregulated circular RNA itchy E3 ubiquitin protein ligase correlates with advanced pathologic T stage, high lymph node metastasis risk and poor survivals in prostate cancer patients

  2019cites this paper
• Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis.

  2019cites this paper
• Advancing Gene Fusion Detection Towards Personalized Cancer Nanodiagnostics

  2019cites this paper
• Detecting long non-coding RNA biomarkers in prostate cancer liquid biopsies: Hype or hope?

  2018cites this paper
• The potential of circulating cell-free RNA as a cancer biomarker: challenges and opportunities

  2018cites this paper
• Anticancer Plants: Mechanisms and Molecular Interactions

  2018cites this paper
• DNA-directed assembly of copper nanoblocks with inbuilt fluorescent and electrochemical properties: Application in simultaneous amplification-free analysis of multiple RNA species

  2018cites this paper
• Omics: A Holistic Approach in Cancer Treatment

  2018cites this paper
• Deep Learning for genomic data analysis

  2017cites this paper
• RNA Biomarkers: Frontier of Precision Medicine for Cancer

  2017cites this paper
• Fusion Genes and their Detection through Next Generation Sequencing in Malignant Hematological Disease and Solid Tumors

  2016cites this paper
• Inherited Variants in SULT1E1 and Response to Abiraterone Acetate by Men with Metastatic Castration Refractory Prostate Cancer.

  2016cites this paper
• Precision management of localized prostate cancer

  2016cites this paper